Promising Pipeline for Treatment of Noninfectious Posterior Uveitis

Agents and delivery mechanisms in development may offer physicians assistance in treating this heterogeneous disorder.

BY STEVEN YEH, MD

Uveitis is a heterogeneous group of conditions that is broadly characterized by intraocular inflammation that can result in visual impairment. Typically classified by anatomic location (anterior, intermediate, posterior, or panuveitis), the inflammation can occur as the result of an infectious process, or it may be related to systemic autoimmune disease. Laboratory testing and appropriate workup may reveal that some cases have no known systemic disease association, either infectious or autoimmune. Other conditions, such as primary intraocular lymphoma, are considered uveitis masquerade syndromes and should be ruled out to ensure that appropriate therapy is initiated.

NONINFECTIONOUS POSTERIOR UVEITIS

Noninfectious uveitis of the posterior segment involves inflammation of the retina and choroid and represents the majority of cases seen in a tertiary referral center for uveitis. Cystoid macular edema (CME) is a leading cause of vision loss in noninfectious posterior uveitis. Both inflammation and alterations in vascular permeability that lead to CME may have to be considered in the treatment of this disease process.

Although treatment algorithms for uveitis are complex (especially if all types and etiologies of uveitis are considered), a concrete, anatomy-based approach can assist in initiation of appropriate therapy. For noninfectious uveitis of the posterior segment, there are many factors to weigh in determining an effective management plan. For example, laterality (whether both eyes are affected), the presence or absence of CME, and the possible side effects of any potential treatments or their interactions with other health conditions should be considered in choosing a therapeutic strategy.

CURRENT THERAPIES

Oral Corticosteroids

Long the mainstay of treatment for posterior noninfectious uveitis, oral corticosteroids are preferred for rapid control of active uveitis. However, significant side effects, both ocular (glaucoma and cataract development) and systemic (weight gain, insomnia, anxiety, gastrointestinal problems, hypertension, and diabetes),
are associated with prolonged use of systemic corticosteroids. Because of these side effects, it is ideal to be able to reduce the steroids to minimal levels (less than 10 mg per day) over a 3-month period. If the active inflammation cannot be controlled in that time frame, other alternatives should be considered.

**Local Corticosteroids**

Local corticosteroid options include intravitreal triamcinolone acetonide injectable suspensions (Triesence, Alcon; Trivaris, Allergan), the 0.59-mg sustained-release fluocinolone acetonide intravitreal implant (Retisert, Bausch + Lomb), and the dexamethasone intravitreal implant (Ozurdex, Allergan). These options constitute the only local treatments for noninfectious uveitis of the posterior segment approved by the US Food and Drug Administration.

In prospective clinical trials, the dexamethasone intravitreal implant was significantly better than sham in achieving visual acuity improvement and improvement in disease activity. The side effect profile was favorable in terms of cataract development or glaucoma and was not significantly greater at 26-week follow-up in patients receiving the dexamethasone intravitreal implant than in those receiving sham treatment.

The fluocinolone acetonide intravitreal implant offers a longer-term sustained-release therapy. It was compared to systemic immunosuppression over 24 months in the

---

### TABLE. EMERGING THERAPIES FOR UVEITIS

<table>
<thead>
<tr>
<th>Therapeutic Agent (Manufacturer)</th>
<th>Drug Class and Delivery Mechanism</th>
<th>US Approval Status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Local Therapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>triamcinolone acetonide (CLS-1001, Clearside Biomedical)</td>
<td>Suprachoroidal injection; corticosteroid</td>
<td>Phase 3 clinical trial set to begin for macular edema associated with noninfectious uveitis</td>
</tr>
<tr>
<td>sirolimus (DE-109, Santen)</td>
<td>Intravitreal; mTOR inhibitor</td>
<td>Phase 3 SAKURA 1 complete; SAKURA 2 under way</td>
</tr>
<tr>
<td>dexamethasone phosphate (EGP-437, Eyegeate Pharma/Valeant)</td>
<td>Intravitreal; corticosteroid to ocular surface</td>
<td>Phase 3 anterior uveitis study planned; may test in posterior noninfectious uveitis in future; also in trials for dry eye</td>
</tr>
<tr>
<td>fluocinolone acetonide implant (Medidur, Alimera Sciences/pSivida)</td>
<td>Sustained-release corticosteroid implant</td>
<td>Phase 3 for posterior uveitis; approved for DME (as Iluvien)</td>
</tr>
<tr>
<td><strong>Systemic Therapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tocilizumab (Actemra, Roche)</td>
<td>Subcutaneous or intravenous injection; IL-6 inhibitor</td>
<td>Phase 1/2 STOP-UVEITIS study; approved for rheumatoid arthritis and other systemic indications</td>
</tr>
<tr>
<td>adalimumab (Humira, AbbVie)</td>
<td>Subcutaneous injection; TNF-α inhibitor</td>
<td>Phase 3 VISUAL studies in uveitis; FDA-approved for several systemic inflammatory conditions</td>
</tr>
<tr>
<td>abatacept (Orence, Bristol-Meyers Squibb)</td>
<td>Intravenous infusion; T-cell antigen</td>
<td>Phase 2 study ongoing</td>
</tr>
<tr>
<td>rituximab (Rituxan, Genentech)</td>
<td>Intravenous infusion of a chimeric monoclonal antibody targeting pan-B-cell marker CD20</td>
<td>Phase 2 study completed for Behçet disease-associated posterior uveitis and retinal vasculitis</td>
</tr>
<tr>
<td>sarilumab (SAR153191, Sanofi/Regeneron)</td>
<td>Subcutaneous injection; IL-6 inhibitor</td>
<td>Phase 2 SATURN study; also in trials for rheumatoid arthritis</td>
</tr>
<tr>
<td>gevokizumab (Xoma 052, Xoma)</td>
<td>IL-1 inhibitor, recombinant humanized antibody</td>
<td>Phase 3 EYEGUARD studies ongoing</td>
</tr>
</tbody>
</table>

Abbreviations: DME, diabetic macular edema; FDA, US Food and Drug Administration; IL, interleukin; mTOR, mammalian target of rapamycin; TNF-α, tumor necrosis factor-alpha
MUST trial.2 Both approaches had similar visual acuity outcomes, but there was a greater decrease in inflammation and vitreous haze in the implant group.2 Eyes that received the fluocinolone acetonide implant had a greater risk for cataract development and glaucoma requiring therapy, which was consistent with prior literature. The authors concluded that individual patient circumstances may dictate whether systemic immunosuppression or local intravitreal sustained-release corticosteroid should be used. For example, pseudophakic patients without glaucoma, with no known history of steroid-associated ocular hypertension, could be considered for the fluocinolone acetonide implant.

Long-Term Therapy
Many patients with chronic uveitis will need long-term therapy to avoid vision loss over time. Examples of such long-term therapy include antimetabolites (methotrexate, azathioprine, mycophenolate), T-cell inhibitors (tacrolimus, cyclosporine), and alkylating agents (chlorambucil, cyclophosphamide), as well as the biologic response modifiers that have recently become commonly used as immunosuppressive agents for uveitis. Although these are all considered off-label uses of drugs that are approved for use in rheumatology, transplant care, and other fields of medicine, retrospective data support their use in patients with uveitis.3,4

EMERGING THERAPIES

Biologics
Established biologic therapies include the tumor necrosis factor-alpha (TNF-α) inhibitors infliximab (Remicade, Janssen) and adalimumab (Humira, AbbVie). Newer agents, including certolizumab (Cimzia, UCB) and golimumab (Simponi, Jansen) have not been studied completely. These medications are manufactured in biologic systems to target specific inflammatory pathways. A panel of uveitis experts recently recommended infliximab and adalimumab as first-line immunomodulatory agents for the treatment of ocular manifestations of Behçet disease and as second-line immunomodulatory agents for the treatment of posterior uveitis.4

Ophthalmologists tend to shy away from systemic therapy, but evidence suggests that these agents should be used for uveitis patients. Long-term immunomodulating agents, although not free of side effects, are generally well-tolerated and effective as corticosteroid-sparing therapy about 60% to 70% of the time.5,7

However, that still leaves a significant gap in treatment. There is an ongoing need for treatments with better (or more targeted) efficacy and improved side effect profiles. Several new and potentially more targeted treatments have been reported in the research pipeline (Table).

mTOR Inhibition
Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor with antiinflammatory and antiangiogenic effects, making it potentially useful in inflammatory and neovascular uveitis. mTOR plays a critical role in stimulating T-cell proliferation, leading to the release of proinflammatory cytokines. By inhibiting mTOR, sirolimus interrupts a critical pathway that perpetuates the inflammatory process, controlling the disease’s progression.

Systemic sirolimus (Rapamune, Pfizer) has been used in organ transplantation and cardiology, so there is good information on safety at much larger doses than would be needed for ocular delivery. The phase 1 and 2 SAVE trials demonstrated that local administration of sirolimus, either intravitreally or subconjunctivally, was safe, tolerable, and effective in reducing vitreous haze and cells, improving visual acuity, and decreasing the need for systemic corticosteroids.8

A formulation of sirolimus for intravitreal delivery (DE-109, Santen) is under investigation in the phase 3 SAKURA 1 and SAKURA 2 trials. These trials are evaluating intravitreal injection of three active doses of sirolimus as monotherapy treatment of active noninfectious posterior uveitis. Santen recently reported that SAKURA 1 met its primary endpoint, with vitreous haze reduced to a score of 0 at 5 months, along with other promising outcomes.9 SAKURA 2 is ongoing.

Alternative Drug Delivery Mechanisms
Clearside Biomedical is developing a method for suprachoroidal delivery of an established therapeutic agent—preservative-free triamcinolone—which could offer potentially less toxicity and less risk of inducing cataract or glaucoma. Early studies in animal models suggest that triamcinolone delivery in the suprachoroidal space supplies high levels of medication to posterior segment tissues (retina, choroid) with lower levels in anterior segment structures.10,11

Other drug delivery mechanisms may also limit the number of injections. EyeGate Pharma, for example, is developing an iontophoresis delivery mechanism for anterior uveitis. These and other novel drug delivery mechanisms warrant exploration over the short and medium term.

Interleukin Blockers and Other New Biologics
A number of new and potentially better targeted systemic medications are in various stages of development as well. Increasing attention has been focused on blocking cytokine mediators of inflammation, specifically interleukins IL-1 and IL-6. Studies have shown efficacy in immune-mediated systemic disorders such as rheumatoid arthritis.12 Additional studies are needed to determine the level of toxicity in

(Continued on page 60)
ocular treatment, frequency of dosing, and the potential to reach the relevant posterior segment structures.

Rituximab (Rituxan, Genentech) is a monoclonal antibody that targets the CD20 surface marker on B cells. It is used to treat lymphoma but has shown some benefit in scleritis and orbital inflammatory conditions. More research in noninfectious uveitis is warranted, but this appears to be a promising agent.

Prospective clinical trials are also under way for treatment of posterior noninfectious uveitis with TNF-α inhibitors already in use for other indications, but these inhibitors have not been compared prospectively against available therapies.

**CONCLUSION**

An array of new drug delivery mechanisms, as well as new local and systemic agents, may play important roles in the treatment of posterior noninfectious uveitis in the future. Because uveitis is such a heterogeneous disorder, it is unlikely that any single therapy will be a magic bullet that can be used in all cases. Rather, in the coming decade, it will be paramount to learn which agent works best for different types of uveitis, how best to combine therapies, and how to minimize toxicity and side effects for our patients.

Steven Yeh, MD, is an associate professor of ophthalmology at Emory University School of Medicine and director of the Uveitis and Vasculitis Section at Emory Eye Center in Atlanta, Ga. He has served as a consultant/advisory board member for Santen, Clearside Biomedical, and Bausch + Lomb. Dr. Yeh may be reached at steven.yeh@emory.edu.